• In March 2026, ImmunityBio faced regulatory and legal pressure as an FDA warning letter over alleged misleading Anktiva promotions was followed by a securities class action lawsuit claiming investors were misled about the drug’s capabilities and the company’s prospects.
• At the same time, ANKTIVA advanced clinically and commercially, with an Independent Data Monitoring Committee confirming adequate power for the pivotal QUILT-2.005 trial and new approvals and guideline recognition extending its bladder cancer footprint in the U.S. and Macau.
• We’ll now examine how the FDA warning letter and related class action could reshape ImmunityBio’s investment narrative built around ANKTIVA.

Uncover the next big thing with 30 elite penny stocks that balance risk and reward.

ImmunityBio Investment Narrative Recap

To own ImmunityBio, you need to believe ANKTIVA can support a durable bladder cancer franchise while the broader pipeline matures, despite current losses and a short cash runway. The FDA warning letter and class action lawsuit raise headline and governance risk but do not directly change the key near term clinical catalyst around QUILT 2.005 or ANKTIVA’s existing approvals, unless future regulatory interactions are affected.

Against that backdrop, the Independent Data Monitoring Committee’s finding that QUILT 2.005 is adequately powered feels especially important. It keeps ImmunityBio on track for a supplemental BLA filing in late 2026 in BCG naive bladder cancer, a setting that sits upstream of today’s BCG unresponsive label and could meaningfully influence how investors think about ANKTIVA’s long term role in bladder cancer care.

Yet while ANKTIVA’s expansion story is compelling, the recent FDA warning letter and securities lawsuit highlight information that investors should be aware of around...

ImmunityBio's narrative projects $1.2 billion revenue and $435.5 million earnings by 2029. This requires 118.9% yearly revenue growth and a $786.9 million earnings increase from -$351.4 million today.

Uncover how ImmunityBio's forecasts yield a $13.50 fair value, a 83% upside to its current price.

Exploring Other Perspectives

Compared with the baseline narrative, the most cautious analysts were already flagging that ImmunityBio’s dependence on ANKTIVA could backfire if adoption or reimbursement disappoint, even while they penciled in revenue reaching about US$895.3 million and earnings of roughly US$418.7 million by 2029, so this latest regulatory and legal scrutiny may prompt you to revisit how comfortable you are with those more optimistic long term assumptions.

Explore 10 other fair value estimates on ImmunityBio - why the stock might be worth less than half the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your ImmunityBio research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
• Our free ImmunityBio research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate ImmunityBio's overall financial health at a glance.

Seeking Other Investments?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Rare earth metals are the new gold rush. Find out which 26 stocks are leading the charge.
• AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.